At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 31 enrolled
Drug / intervention
Simvastatin +1 moredrug
Likely dose
Simvastatin 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo Controlled Clinical Trial to Evaluate the Effects of Simvastatin Treatment on Measurements of Lipidomic Biomarkers in Men With Dyslipidemia
In Brief
A Phase 1 clinical trial evaluating Simvastatin and Placebo for Hypercholesterolemia, Dyslipidemia. Completed, enrolled 31 participants.
Detailed Summary
The purpose of this study was to provide human lipidomics standards with simvastatin treatment that were to be used for comparison with similar preclinical studies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypercholesterolemia, Dyslipidemia
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2009
First PostedJul 2009
Primary CompletionOct 2009
TodayJul 2026
First PostedJul 8, 2009
Enrollment StartJul 1, 2009
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 17.0 years ago
Interventions
Simvastatindrug
40 mg once daily for 2 weeks
Placebodrug
Placebo, matching the simvastatin (40 mg) tablet as a single oral daily dose for 2 weeks